Proc. Nati. Acad. Sci. USA
Vol. 84, pp. 8282-8286, December 1987
Biochemistry
Isolation and partial characterization of follistatin: A single-chain
Mr 35,000 monomeric protein that inhibits the release of
follicle-stimulating hormone
(ovary/pituitary/luteinizing hormone/gonadotropins/porcine foilicular fluid)
NAOTO UENO, NICHOLAS LING*, SHAO-YAO YING, FREDERICK ESCH, SHUNICHI SHIMASAKI,
AND ROGER GUILLEMIN
The Salk Institute for Biological Studies, Laboratories for Neuroendocrinology, 10010 North Torrey Pines Road, La Jolla, CA 92037
Contributed by Roger Guillemin, August 6, 1987
homologous to each other, were found to be structurally
related to a homodimeric protein, transforming growth factor
,3, which has totally different biological activities (10). Moreover, in addition to the inhibins, two FSH-releasing proteins
of apparent Mr 24,000, named activin A and activin AB, also
were isolated from porcine follicular fluid (12-14). The former
was characterized as a homodimer composed of two ,B
subunits of inhibin A linked by disulfide bridge(s), while the
latter is a heterodimer composed of the 13 subunits of inhibins
A and B.
In our original work on the isolation of the two Mr 32,000
heterodimeric inhibins from porcine ovarian follicular fluid,
we had noted a side fraction migrating at the beginning of the
first reversed-phase high-performance liquid chromatogram
ahead of the activins and inhibins, which also could specifically suppress pituitary FSH secretion in the inhibin bioassay. In this paper we present the purification and isolation of
this FSH release-inhibiting protein named "follistatin," present in porcine ovarian follicular fluid, and show that it is a
glycoprotein of Mr 35,000 composed of a single polypeptide
chain.
A Mr 35,000 protein with follicle-stimulating
ABSTRACT
hormone release-inhibitory activity was isolated from porcine
ovarian follicular fluid by heparin-Sepharose affinity chromatography, gel fitration on Sephacryl S-200, and multiple steps
of high-performance liquid chromatography. The isolated
molecule is highly enriched in cysteines and is composed of a
single polypeptide chain. In addition, it has no sequence
homology with the previously characterized follicular fluid
inhibins, which are heterodimeric proteins of Mr 32,000 with
follicle-stimulating hormone release-inhibiting activity. This
protein specifically inhibits the basal secretion of follicle-stimulating hormone, but not that of luteinizing hormone, in the rat
anterior pituitary monolayer culture system with a halfmaximal effective dose of 2.5-6.0 ng/ml. Another form of the
molecule of Mr 32,000 present in much lower concentration in
follicular fluid was also isolated. It may differ from the Mr
35,000 form in glycosylation or carboxyl-terminal truncation.
We suggest that this compound be called "follistatin" to signify
its structural difference from inhibin.
Secretion of pituitary follicle-stimulating hormone (FSH) is
principally regulated by the hypothalamic hypophysiotropic
gonadotropin-releasing hormone and gonadal steroids (1).
But for many years the existence of a nonsteroidal, watersoluble factor from the gonad that feeds back on the pituitary
specifically to suppress the secretion of FSH has been
advocated by many researchers (2); the name "inhibin" was
coined in 1932 to describe such a factor (3). However, the
search for the elusive inhibin did not succeed until 1985, when
two closely related glycoproteins of apparent Mr 32,000,
named inhibins A and B, were isolated from porcine ovarian
follicular fluid (4-6). Subsequently, a similar Mr 32,000
inhibin was also isolated from bovine ovarian follicular fluid
(7, 8). Each inhibin was found to be composed of a common
Mr 18,000 glycosylated a subunit linked by interchain disulfide bond(s) to either a PA subunit of Mr 14,700 to yield inhibin
A or a PB subunit of Mr 14,000 to form inhibin B; the two 13
subunits were closely related but distinct from each other (4).
The common a subunit can exist also in a larger molecular
form of Mr 44,000 and, in combination with the 13 subunit of
inhibin A, can form an inhibin of Mr 56,000 (9).
Using partial amino acid sequence information, the messages encoding the a, PA, and PB subunits of porcine inhibin
were cloned from an ovarian cDNA library (10) as were the
a and PA subunits of bovine inhibin (11). DNA sequence
analyses showed that all of the subunits were initially
synthesized as large precursor proteins with the mature
subunits residing at the carboxyl-terminal portion of the
precursors. Surprisingly, the two P subunits, besides being
MATERIALS AND METHODS
Bioassay. Throughout the purification procedure, the FSH
release-inhibiting activity was monitored by an in vitro bioassay using immature female rat anterior pituitary monolayer
culture as in the isolation of the inhibins (4).
Reversed-Phase HPLC. The reversed-phase HPLC system
used for the purification of the follistatin consisted of a
Beckman series 322 gradient liquid chromatography system
equipped with a Spectroflow 757 UV detector (Kratos,
Ramsey, NJ), a Soltec 220 recorder (Soltec, Sun Valley, CA),
and a Redirac 2112 fraction collector (LKB). Two reversedphase HPLC solvent systems were used. In the triethylammonium phosphate (Et3NHP1) system, solvent A consists of
0.25 M Et3NHP6 (pH 3); solvent B is 80% (vol/vol) acetonitrile in solvent A. In the CF3COOH system, solvent A
contains 1 ml of CF3COOH in 999 ml of water; solvent B is
1 ml of CF3COOH in 199 ml of water and 800 ml of acetonitrile. Other reversed-phase HPLC conditions are given in
the legends to Figs. 1 and 2.
Anion-Exchange HPLC. The anion-exchange HPLC system used for the purification consisted of a Beckman series
332 gradient liquid chromatography system equipped with a
Beckman 160 UV detector, a Soltec 1242 recorder, and a
Redirac 2112 fraction collector. The solvent system used for
the anion-exchange HPLC consisted of buffer A, which is
The publication costs of this article were defrayed in part by page charge
payment. This article must therefore be hereby marked "advertisement"
in accordance with'18 U.S.C. §1734 solely to indicate this fact.
Abbreviations: FSH, follicle-stimulating hormone; Et3NHPj, triethylammonium phosphate.
*To whom reprint requests should be addressed.
8282
Biochemistry: Ueno et al.
Proc. Natl. Acad. Sci. USA 84 (1987)
0.01 M Na2HPO4 (pH 6.5), and buffer B, which is 1 M NaCl
in buffer A.
Initial Purification. The starting material for the purification of the follistatin was a side fraction derived from the
purification of the porcine ovarian inhibins and activins (4,
12, 14). Briefly, porcine follicular fluid was processed batchwise through a heparin-Sepharose affinity chromatography
column, and the adsorbed protein was further size-fractionated on a Sephacryl S-200 column in acidic medium. Fractions containing the Mr 32,000 inhibins and FSH-releasing
activities from the column (fractions 35-43 in figure la of ref.
4) were pooled and lyophilized. The lyophilized material (=40
mg) was dissolved in 40 ml of 0.2 M acetic acid and filtered
through a Millex-HA 0.45-,um filter (Millipore). The filtrate
was applied directly to a 10 x 250 mm Vydac 5-gm C4 column
(The Separation Group, Hesperia, CA). After all of the
filtrate had been loaded, the column was washed with solvent
8283
A until the UV absorption reached baseline. The inhibins and
activins were separated with a linear gradient of 27-36%
acetonitrile in the Et3NHPj solvent system in 90 min at a flow
of 3 ml/min. Three zones of FSH release-inhibiting activity
corresponding to inhibins A and B and follistatin were
detected, as were two zones of FSH-releasing activity as
shown in Fig. la. Inhibins A and B, as well as the FSH-releasing
substances (activin A and activin AB) have been purified to
homogeneity and their primary structures characterized as
reported (4, 10, 12, 14). The remaining FSH release-inhibiting
zone migrating ahead of the activins and inhibins on the HPLC
column was saved for the present work.
NaDodSO4/PAGE. The follistatin isolated from the final
reversed-phase HPLC purification was analyzed in a 1-mm
thick, 10% acrylamide gel by the method of Laemmli (15).
The protein band was revealed by Coomassie blue reagent
(Bio-Rad). The following molecular weight standards were
a
A.,
-
% Acel,tonitrile
0.04-
FSH
ng/mi
-307
2025
Li-6-
-1 5
0.0 1--1 0
-5
C
10
20
30
Fraction No.
40
50
FIG. 1. (a) Reversed-phase HPLC purification of the FSH release-inhibiting as well as FSH-releasing proteins recovered from gel filtration.
Three zones of FSH release-inhibiting activity (inhibins A, B, and follistatin) and two zones of FSH-releasing activity (activins A and AB),
indicated by the solid bars, were recovered. (b) Reversed-phase HPLC purification of follistatin. Active fractions 3 and 4 in a were pooled and,
after dilution with 0.2 M acetic acid, applied directly onto a Vydac C4 column and eluted with the indicated gradient of acetonitrile in the
CF3COOH system at 3 ml/min. (c) The active material (denoted by solid bar in b) was pooled and, after removal of the acetonitrile and adjustment
to pH 6.5, was applied to a Spherogel-TSK DEAE-5PW column. The activity was separated by the indicated gradient of NaCI in sodium
phosphate buffer.
8284
Biochemistry: Ueno et al.
Proc. Natl. Acad. Sci. USA 84 (1987)
activins, were pooled, mixed with an equal volume of 0.2 M
acetic acid, and applied directly onto a 10 x 250 mm Vydac
5-,um C4 column as before (4). The active material was eluted
from the column with a linear gradient of 21-30% acetonitrile
in the CF3COOH system in 90 min at a flow of 3 ml/min as
shown in Fig. lb. Fractions with FSH release-inhibiting
activity (fractions 19-23) detected by the bioassay were pooled and, after the acetonitrile was removed in a Speed-Vac
concentrator (Savant) and the pH was adjusted to 6.5 with 0.1
M ammonium hydroxide, were pumped directly onto a 7.5 X
75 mm Spherogel-TSK 10-pum DEAE-5PW column (Toyo
Soda, Tokyo). After loading, the column was washed with
buffer A until the UV absorption reached baseline. The
follistatin activity was separated with a linear gradient of
0-0.3 M NaCl in 90 min at a flow rate of 1 ml/min as shown
in Fig. ic. The active material eluted in fractions 19-22 was
pooled and, after dilution to 4 times its original volume with
0.2 M acetic acid, was further purified on a 10 x 250 mm
Vydac 5-,um C4 column and eluted with a linear gradient of
21-30% acetonitrile in the CF3COOH solvent system in 90
used to calibrate the gel: bovine serum albumin (Mr 67,000),
ovalbumin (Mr 43,000), and a chymotrypsinogen (Mr 25,700).
The purified protein was analyzed under nonreducing and
reducing conditions as before (4).
Amino Acid Analyses and Microsequencing. Amino acid
analyses and amino-terminal sequence determination of
follistatin were performed as described (16, 17).
Concanavalin A-Sepharose 4B Affinity Chromatography.
Approximately 1 ,tg of the purified Mr 35,000 follistatin was
iodinated with lactoperoxidase (Calbiochem), and the labeled
protein was purified on a 0.7 x 50 cm Sephadex G-50 column
with 0.01 M phosphate buffer (pH 7.5). The labeled follistatin
was loaded onto a 1-ml concanavalin A-coupled Sepharose
4B column (Sigma) and washed successively with the loading
buffer, 0.2 M and 1.0 M methyl a-D-mannopyranoside in
loading buffer, and 0.1 M acetic acid as described (18).
RESULTS
For the purification of follistatin, fractions 3 and 4 in Fig. la,
saved from the previous purification of the inhibins and
a
I
b
A
210(
)
0.41
0.3-
i
-] FSH
% Acetonitrile
I
IX
ng/ml
-7 0
D
-60
-50
I
-40
-30
-20
-10
l
l
ll
10
C
20
30
40
50
A280(-)
0.1 8-
0.16
% Acetonitrile
0.14-
-0
0.12-
-70
0.10-
0
.1
.1
,f
0.08-
-50
0.06-
-40
0.04-
-30
0.02-
-20
-.s f
a
I
I
I
111111111 111111111 111111
20
10
Fraction No.
30
40
FIG. 2. Reversed-phase HPLC purification of follistatin. (a) Active fractions (solid bar in Fig. 1c) were pooled and after dilution were applied
directly onto a Vydac C4 column and eluted with the indicated gradient of acetonitrile in the CF3COOH system at 1 ml/min. (b) The active
material (denoted by solid bar I in a) was pooled, diluted, and chromatographed on a Vydac phenyl column with the indicated gradient of
acetonitrile in the Et3NHPj system at 1 ml/min. (c) The material denoted by the solid bar in b was pooled and concentrated by chromatography
on an Aquapore RP-300 column with the indicated gradient of acetonitrile in the CF3COOH system at 0.5 ml/min.
Biochemistry: Uen'o et al.
min at a flow of 1 ml/min as shown in Fig. 2a. The active
material eluted in fractions 33-35 (peak I) was pooled and
diluted to twice its original volume and rechromatographed
on a 10 x 250 mm Vydac 5-pm phenyl column with a linear
gradient of 18-27% acetonitrile in the Et3NHPj system in 90
min at a flow rate of 1 ml/min as shown in Fig. 2b. Finally,
the active material in fractions 34-36 was pooled and, after
dilution with 0.2 M acetic acid, was concentrated by chromatography on a 4.6 x 250 mm Aquapore 10-ptm RP-300
column with a linear gradient of 20-80% acetonitrile in the
CF3COOH system in 60 min at a flow rate of 0.5 ml/min as
shown in Fig. 2c. Altogether, -400 pAg of follistatin was
isolated from 18 liters of follicular fluid.
The purified protein showed half-maximal inhibition of
FSH release at a concentration of 2.5-6.0 ng/ml (0.07-0.17
nM). It had no effect on the secretion of luteinizing hormone,
growth hormone, prolactin, or thyroid-stimulating hormone.
Amino acid analyses showed that follistatin, like inhibins A
and B, is highly enriched in cysteines (Table 1). On NaDodSO4/PAGE under nonreducing conditions, follistatin showed
a single band migrating at an apparent Mr of 35,000 as shown
in Fig. 3a. In contrast to inhibins A and B, follistatin exhibited
a single band that migrated at an apparent Mr of 42,000 under
reducing conditions (Fig. 3b), indicating that it is composed
of a single polypeptide chain. Microsequence analyses of
follistatin revealed its amino terminus to be Gly-Asn-CysTrp-Leu-Arg-Gln-Ala. In addition, 63% of the labeled
follistatin was retained on the concanavalin A-Sepharose 4B
affinity column, which could be displaced with 0.2 M methyl
a-D-mannopyranoside, indicating that follistatin is glycosylated.
Using similar reversed-phase HPLC conditions (data not
shown), a Mr 32,000 form (Fig. 4a) of follistatin with an
identical amino-terminal sequence as that of the Mr 35,000
follistatin was isolated from fractions 36 and 37 of Fig. 2a
(peak II). Its amino acid composition is related to the Mr
35,000 form (Table 1), and upon reduction, this protein
migrated as a single band at an apparent Mr of 40,000 on
NaDodSO4/PAGE (Fig. 4b).
Table 1. Amino acid composition of purified follistatin from
porcine follicular fluid
Amino acid
Mr 35,000 form
Mr 32,000 form
±
Asx
34.1 0.2
28.4 ± 0.0
Thr
17.7 ± 0.3
15.9 ± 0.0
Ser
25.6 ± 0.2
22.2 ± 0.2
31.1 ± 0.1
Glx
36.7 ± 0.1
24.5 ± 0.0
23.3 ± 0.2
Gly
Ala
17.1 ± 0.2
15.6 ± 0.0
Val
15.5 ± 0.3
14.0 ± 0.0
Met
3.2 ± 0.1
3.4 ± 0.0
10.1 ± 0.1
7.5 ± 0.1
Ile
Leu
20.9 ± 0.2
19.1 ± 0.0
9.5 ± 0.1
8.8 ± 0.1
Tyr
Phe
5.0 ± 0.1
4.6 ± 0.0
His
2.2 ± 0.0
2.0 ± 0.0
5.8 ± 0.1
5.6 ± 0.1
Trp
25.2 ± 0.1
26.2 ± 0.0
Lys
12.7 ± 0.1
13.7 ± 0.1
Arg
35.9 ± 0.2
33.5 ± 0.1
Cys*
Pro
13.5 ± 0.3
13.0 ± 0.1
Values represent means ± SD of two analyses, normalized to a
protein of 35,000 daltons for the Mr 35,000 form of follistatin and a
protein of 32,000 daltons for the Mr 32,000 form.
*Determined as cysteic acid after performic acid oxidation.
Proc. Natl. Acad. Sci. USA 84 (1987)
a.
8285
b.
67-_
67-*
43 _-am-
4-42
43_01-
_i -35
25.7-4_
25.7 -_
FIG. 3. NaDodSO4/PAGE analysis of the purified Mr 35,000
follistatin under nonreducing conditions (a) and under reducing
conditions (b). Positions of the molecular weight standards (shown x
10-3) are indicated at the left.
DISCUSSION
Two novel proteins with FSH release-inhibiting activity were
purified from porcine follicular fluid by using essentially the
same procedures employed for the isolation of the inhibins
and activins (4, 12, 14). The protein obtained in much higher
yield has an apparent Mr of 35,000, whereas the other has an
apparent Mr of 32,000. Both proteins were found to have an
identical amino terminus and are composed of a single
polypeptide chain. In view of the similar amino acid compositions and identical amino termini, the two forms of follistatin are probably related, and their difference in molecular
size might be due to variation in glycosylation or carboxylterminal truncation.
Aside from the high content of cysteines, there is no
relation in amino acid composition between follistatin and
inhibins A and B. In addition, follistatin is a monomeric
protein, whereas inhibins A and B and all higher molecular
weight inhibins reported thus far are heterodimers (9, 19).
In a recent publication, Leversha et al. (20) reported the
copurification of a Mr 29,000-30,000 single-chain protein
together with inhibin A from ovine follicular fluid. They
demonstrated that this protein also has FSH release-inhibit-
a.
b.
67_-*
4-40
25.7-_
25.7-_0
FIG. 4. NaDodSO4/PAGE analysis of the purified Mr 32,000
follistatin under nonreducing conditions (a) and under reducing
conditions (b). Positions of the molecular weight standards (shown x
10-) are indicated at the left.
8286
Biochemistry: Ueno et al.
ing activity and upon reduction migrated as a single band of
apparent Mr 36,000 on NaDodSO4/PAGE. However, no
further purification and characterization of this protein was
attempted. It is interesting to speculate that this single-chain
protein with inhibin-like activity may be related to the follistatin isolated in our laboratory.
At present we do not know the physiological significance
of follistatin. Preliminary biological studies showed that this
molecule can specifically inhibit the spontaneous release of
pituitary FSH with no effects on luteinizing hormone. Its
relative potency is about one-third that of inhibin A (4). Undoubtedly, more physiological studies will be forthcoming to
unravel the function of this new ovarian regulatory protein.
We thank F. Castillo, R. Schroeder, M. Regno, A. Becker, J.
Czvik, G. Swanson, and P. Tan for technical assistance and D.
Higgins for preparing the manuscript. This work was supported by
National Institute of Child Health and Human Development contract
N01-HD-6-2944, National Institutes of Health Program Project
Grants HD-09690 and DK-18811, and a grant from the Robert J. and
Helen C. Kleberg Foundation.
1. Griffin, J. E. & Wilson, J. D. (1985) in Williams' Textbook of
Endocrinology, eds. Wilson, J. D. & Foster, D. W. (Saunders,
Philadelphia), 7th Ed., pp. 259-311.
2. Franchimont, P., Verstraelen-Proyord, J,, Hazee-Hagelstein,
M. T., Renard, Ch., Demoulin, A., Bourguignon, J. P. &
Hustin, J. (1979) Vitam. Horm. (N. Y.). 37, 243-302.
3. McCullagh, D. R. (1932) Science 76, 19-20.
4. Ling, N., Ying, S.-Y., Ueno, N., Esch, F., Denoroy, L. &
Guillemin, R. (1985) Proc. Natl. Acad. Sci. USA 82,
7217-7221.
5. Miyamoto, K., Hasegawa, Y., Fukuda, M., Nomura, M.,
Igarashi, M., Kangawa, K. & Matsuo, H. (1985) Biochem.
Hiophys. Res. Commun. 129, 396-403.
6. Rivier, J., Spiess, J., McClintock, R., Vaughan, J. & Vale, W.
(1985) Biochem. Biophys. Res. Commun. 133, 120-127.
Proc. Natl. Acad. Sci. USA 84 (1987)
7. Fukuda, M., Miyamoto, K., Hasegawa, Y., Nomura, M.,
Igarashi, M., Kangawa, K. & Matsuo, H. (1986) Mol. Cell.
Endocrinol. 44, 55-60.
8. Robertson, D. M., deVos, F. L., Foulds, L. M., McLachlan,
R. I., Burger, H. G., Morgan, F. J., Hearn, M. T. W. &
deKretser, D. M. (1986) Mol. Cell. Endocrinol. 44, 271-277.
9. Robertson, D. M., Foulds, L. M., Leversha, L., Morgan,
F. J., Hearn, M. T. W., Burger, H. G., Wettenhall, R. E. H.
& deKretser, D. M. (1985) Biochem. Biophys. Res. Commun.
126, 220-226.
10. Mason, A. J., Hayflick, J. S., Ling, N., Esch, F., Ueno, N.,
Ying, S.-Y., Guillemin, R., Niall, H. & Seeburg, P. (1985)
Nature (London) 318, 659-663.
11. Forage, R. G., Ring, J. M., Brown, R. W., McInerney, B. V.,
Cobon, G. S., Gregson, R. P., Robertson, D. M., Morgan,
F. J., Hearn, M. T. W., Findlay, J. K., Wettenhall, R. E. H.,
Burger, H. G. & deKretser, D. M. (1986) Proc. Natl. Acad.
Sci. USA 83, 3091-3095.
12. Ling, N., Ying, S.-Y., Ueno, N., Shimasaki, S., Esch, F.,
Hotta, M. & Guillemin, R. (1986) Nature (London) 321,
779-792.
13. Vale, W., Rivier, J., Vaughan, J., McClintock, R., Corrigan,
A., Woo, W., Karr, D. & Spiess, J. (1986) Nature (London)
321, 776-779.
14. Ling, N., Ying, S.-Y., Ueno, N., Shimasaki, S., Esch, F.,
Hotta, M. & Guillemin, R. (1986) Biochem. Biophys. Res.
Commun. 138, 1129-1137.
15. Laemmli, U. (1970) Nature (London) 227, 1677-1685.
16. Bohlen, P. & Schroeder, R. (1982) Anal. Biochem. 126,
144-152.
17. Esch, F. (1984) Anal. Biochem. 136, 39-47.
18. Shibasaki, T., Ling, N. & Guillemin, R. (1980) Nature (London) 285, 416-417.
19. Miyamoto, K., Hasegawa, Y., Fukuda, M. & Igarashi, M.
(1986) Biochem. Biophys. Res. Commun. 136, 1103-1109.
20. Leversha, L. J., Robertson, D. M., deVos, F. L., Morgan,
F. J., Hearn, M. T. W., Wettenhall, R. E. H., Findlay, J. K.,
Burger, H. G. & deKretser, D. M. (1987) J. Endocrinol. 113,
213-221.